Additional studies are also needed to determine if targeted inhibition of FAS pathways in macrophages is sufficient to reverse inflammasome activation and subsequently improve NAFLD pathology. The gene discussed is FAS; the disease is metabolic dysfunction-associated steatotic liver disease.